NasdaqGS:BEAMBiotechs
Assessing Beam Therapeutics (BEAM) Valuation After Major BEACON Trial Milestone For Sickle Cell Therapy
Beam Therapeutics (BEAM) just cleared an important clinical hurdle, with Phase 1/2 BEACON trial results for its sickle cell therapy risto cel published in The New England Journal of Medicine.
See our latest analysis for Beam Therapeutics.
At a share price of US$24.66, Beam’s recent news around risto cel and BEAM-302 comes after a mixed stretch. A 1-day share price return of 1.82% and 7-day share price return of 11.13% contrast with a 90-day share price return of 9.14% and a 5-year total...